
Opinion|Videos|November 27, 2025
Barriers to Adoption of SC Therapies
Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Advertisement
Episodes in this series

Panelists discuss how barriers such as provider hesitancy, reimbursement concerns, and logistical complexities slow the adoption of subcutaneous (SC) therapies. They propose strategies including education, workflow redesign, and advocacy to increase confidence in SC delivery. The discussion emphasizes that as data accumulate and experience grows, institutional and cultural shifts will further integrate SC therapy
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
2
Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI
3
FDA Approves First Disease-Modifying Treatment for AxD
4
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
5





